# Impact of Agalsidase Alfa Therapy on Cardiac funcTION in Patients With Fabry's Cardiomyopathy

> **NCT03230591** · — · UNKNOWN · sponsor: **Yonsei University** · enrollment: 25 (estimated)

## Conditions studied

- Fabry Disease

## Interventions

- **OTHER:** Echocardiography

## Key facts

- **NCT ID:** NCT03230591
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-07-12
- **Primary completion:** 2025-01
- **Final completion:** 2025-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2021-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03230591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03230591, "Impact of Agalsidase Alfa Therapy on Cardiac funcTION in Patients With Fabry's Cardiomyopathy". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03230591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*